LMR Partners
MDGL icon

LMR Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

LMR Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,500
Closed -$2.31M – 1546
2024
Q4 		$2.31M Buy
+7,500
New +$2.11M 0.02% 562
2024
Q2 		– Sell
-2,500
Closed -$668K – 1226
2024
Q1 		$668K Sell
2,500
-17,500
-88% -$4.12M 0.01% 729
2023
Q4 		$4.63M Buy
+20,000
New +$3.5M 0.05% 325

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Paulson & Co
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

LMR Partners's MDGL Position: Q2 2026 in Review

LMR Partners opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 2,032 shares worth $1.09M. The stake represents ﹤0.01% of the portfolio and ranks #1036 among its holdings. This is a return to the name: LMR Partners previously reported a position in MDGL as recently as Q2 2025.

LMR Partners first reported a position in MDGL in Q2 2016 and has held it in 8 quarters since. The position peaked at $12M in Q4 2023. 415 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • LMR Partners held 2,032 shares of Madrigal Pharmaceuticals worth $1.09M as of Q2 2026.
  • Madrigal Pharmaceuticals was a new LMR Partners position in Q2 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of LMR Partners's portfolio in Q2 2026, its #1036 holding.
  • LMR Partners first reported a position in Madrigal Pharmaceuticals in Q2 2016 and has held it in 8 quarters since.
  • LMR Partners's Madrigal Pharmaceuticals position peaked at $12M in Q4 2023.
  • 415 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.